Skip to main content
UniHealth

Doctor search

Ghassan Al-Jazayrly, MD

Hematology/Oncology · Los Angeles

NPI 1679590566

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Offices
2
Since medical school
41 years
Graduated 1985

Offices

2 locations · Complete Care Community Health Center, Inc · 45 clinicians in this group

Looking this up.

Hospitals listed: 757125 · Glendale Mem Hospital & Hlth Center · Hollywood Presbyterian Medical Center. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Al-Jazayrly’s office at (323) 266-6700 to ask if they take your plan before you enroll.

California Medical Board record

Licence A52470 · Current

Licensed to practise in California · since 1993 · expires 2027-04-30 · University of Aleppo Faculty of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Glendale Mem Hospital & Hlth CenterGlendale, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.105, Oct 2024 – Sep 2025
  • Hollywood Presbyterian Medical CenterLos Angeles, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPatients rate it 2 of 5 · 60% would definitely recommend it
    Overall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.016, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.165, Oct 2024 – Sep 2025
See every measure and the patient survey for Glendale Mem Hospital & Hlth Center

Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Glendale Mem Hospital & Hlth Center
Clostridium Difficile (C.Diff)Infections0.105BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.94 (0 to 1.97) · 609 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.49 to 1.24)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths154.55 (98.55 to 210.56) · 42 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 26 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 75 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths11.1 · 140 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.9 · 325 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths13.6 · 373 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths12.5 · 166 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.2 · 1,586 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.17 (0 to 0.39) · 3,962 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.27 (0.07 to 0.47) · 4,083 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.07 (0.76 to 5.38) · 734 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.6 (0 to 3.29) · 196 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.98 (0.38 to 3.58) · 750 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.99 (0.29 to 17.7) · 201 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths6.34 (2.25 to 10.43) · 187 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.72 (0.21 to 3.23) · 126 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.2 (0 to 0.95) · 3,409 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths2.7 · 205 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.349No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.343No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.42No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.269No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.7 · 155 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 404 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-15.2 · 151 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.2 · 421 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits34.6 · 433 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17.4 · 368 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits4.4 · 182 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.3 · 42 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.5 · 99 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.5 (9.5 to 16.5) · 613 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.1 (0.8 to 1.4) · 158 casesNo differentJan 2024 – Dec 2024

What patients said (565 patients answered, 10% of those asked)

Patient survey stars by topic at Glendale Mem Hospital & Hlth Center
Cleanliness3
Nurse communication2
Doctor communication2
Communication about medicines2
Discharge information2
Overall hospital rating3
Quietness3
Recommend hospital3
Share of patients giving the best answer at Glendale Mem Hospital & Hlth Center
Room was "always" clean70%
Nurses "always" communicated well75%
Doctors "always" communicated well74%
Staff "always" explained59%
Yes, staff "did" give patients this information83%
Yes, staff "did" give patients information about help after discharge80%
Doctors "always" explained things so they could understand70%
Doctors "always" listened carefully72%
Doctors "always" treated them with courtesy and respect78%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications74%
Nurses "always" explained things so they could understand72%
Nurses "always" listened carefully73%
Nurses "always" treated them with courtesy and respect82%
"Always" quiet at night52%
"YES", patients would definitely recommend the hospital67%
Staff "always" explained possible side effects43%
Yes, staff "did" give patients information about possible symptoms86%
See every measure and the patient survey for Hollywood Presbyterian Medical Center

Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 1 better, 5 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Hollywood Presbyterian Medical Center
Clostridium Difficile (C.Diff)Infections0.016BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.165BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.92 (0 to 1.95) · 687 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.51 to 1.21)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths140.36 (84.45 to 196.27) · 30 casesNo differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths6.8 · 77 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths11 · 78 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths7.7 · 187 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths14.5 · 289 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths13.7 · 93 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.9 · 1,577 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.17 (0 to 0.39) · 3,875 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.31 (0.11 to 0.51) · 3,998 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.09 (1.83 to 6.36) · 761 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.59 (0 to 3.29) · 396 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.27 (0.67 to 3.87) · 834 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths6.18 (0 to 14.44) · 416 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.49 (1.39 to 9.58) · 287 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.68 (0.18 to 3.18) · 172 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.36 (0 to 1.04) · 3,450 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 209 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.363No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.8 · 124 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits21.9 · 304 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-17.4 · 79 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits22.2 · 231 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits40.9 · 284 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.3 · 331 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits5.4 · 200 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 106 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.5 (9.3 to 16.8) · 72 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.6 to 1.2) · 137 casesNo differentJan 2024 – Dec 2024

What patients said (1,225 patients answered, 24% of those asked)

Patient survey stars by topic at Hollywood Presbyterian Medical Center
Cleanliness2
Nurse communication1
Doctor communication2
Communication about medicines2
Discharge information2
Overall hospital rating2
Quietness2
Recommend hospital2
Share of patients giving the best answer at Hollywood Presbyterian Medical Center
Room was "always" clean64%
Nurses "always" communicated well66%
Doctors "always" communicated well69%
Staff "always" explained50%
Yes, staff "did" give patients this information79%
Yes, staff "did" give patients information about help after discharge75%
Doctors "always" explained things so they could understand64%
Doctors "always" listened carefully67%
Doctors "always" treated them with courtesy and respect75%
Patients who gave a rating of "9" or "10" (high)58%
Staff "always" explained new medications66%
Nurses "always" explained things so they could understand62%
Nurses "always" listened carefully63%
Nurses "always" treated them with courtesy and respect73%
"Always" quiet at night40%
"YES", patients would definitely recommend the hospital60%
Staff "always" explained possible side effects35%
Yes, staff "did" give patients information about possible symptoms82%

Original Medicare doctor bills

$475,501

Medicare paid this office $475,501 for 228 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes159$95,200$58
Initial hospital care with moderate level of medical decision making at least 75 minutes175$27,743$129
Administration of chemotherapy into vein, 1 hour or less26$20,350$112
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less16$3,011$25
Administration of additional new drug or substance into vein, 1 hour or less11$2,992$55
See all 8 services
Every Original Medicare service billed
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes159$95,200$58
Initial hospital care with moderate level of medical decision making at least 75 minutes175$27,743$129
Administration of chemotherapy into vein, 1 hour or less26$20,350$112
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less16$3,011$25
Administration of additional new drug or substance into vein, 1 hour or less11$2,992$55
Injection of drug or substance under skin or into muscle35$1,658$11
Injection, dexamethasone sodium phosphate, 1 mg12$1None
Injection, denosumab, 1 mg23$1None

Procedures year by year

Procedures billed to Original Medicare by year
Procedure201920202021202220232024
Biopsy of bone marrow11–––––

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

228 Original Medicare patients in 2024. Average age 74 · Under 65 10% · 85 and older 18% · Women 50% · Also on Medicaid 93% · Health risk score 3.43. Sicker patients than 9 in 10 peers; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 75% · Diabetes 69% · Chronic kidney disease 59% · Heart failure 54% · Coronary heart disease 51% · Depression 46% · Cancer 44% · COPD 44% · Atrial fibrillation 37% · Dementia 36% · Stroke 23%.

The office billed $927,581, Medicare allowed $597,948 and paid $475,501; for 5,459 services of 49 kinds; $318,827 of it was for drugs given in the office and $156,674 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20242285,459743.43$927,581$475,501
202319710,940753.20$406,452$162,365
20222558,910743.29$643,931$248,051
20212679,904743.56$766,802$298,794
20202507,167734.13$654,545$266,342
20193159,650733.74$616,189$233,526
201842287,989753.27$1,770,381$909,379
2017535159,809733.20$2,839,510$1,227,741
2016532200,997742.99$3,601,195$1,520,134
2015591208,026743.22$3,336,963$1,436,642
2014525154,945733.25$2,431,686$1,044,357
201360863,740733.02$2,439,085$1,117,875

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 5 services

Original Medicare services billed in 2023
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes143$106,724$66
Initial hospital care with moderate level of medical decision making at least 75 minutes157$26,637$142
Administration of chemotherapy into vein, 1 hour or less20$16,929$114
Injection of drug or substance under skin or into muscle27$1,319$10
Injection, denosumab, 1 mg22$8None

2022: 9 services

Original Medicare services billed in 2022
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes196$145,360$60
Initial hospital care with moderate level of medical decision making at least 75 minutes202$43,365$162
Administration of chemotherapy into vein, 1 hour or less27$24,832$115
Injection, nivolumab, 1 mg15$7,960None
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less14$3,436$26
Administration of additional new drug or substance into vein, 1 hour or less13$2,426$58
Injection of drug or substance under skin or into muscle33$2,183$11
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle14$2,097$25
Injection, denosumab, 1 mg23$1None

2021: 13 services

Original Medicare services billed in 2021
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes212$145,430$61
Initial hospital care with moderate level of medical decision making at least 75 minutes216$48,507$166
Administration of chemotherapy into vein, 1 hour or less31$38,560$123
Injection, bevacizumab, 10 mg14$22,817None
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less21$8,399$28
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less15$7,171$63
Administration of additional new drug or substance into vein, 1 hour or less19$6,576$62
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle14$3,023$25
Injection of drug or substance under skin or into muscle34$2,140$10
Administration of chemotherapy into vein, each additional hour13$1,631$26
Injection, ondansetron hydrochloride, per 1 mg18$18None
Injection, dexamethasone sodium phosphate, 1 mg17$18None
Injection, denosumab, 1 mg25$1None

2020: 8 services

Original Medicare services billed in 2020
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes176$109,313$62
Initial hospital care with moderate level of medical decision making at least 75 minutes188$39,658$171
Administration of chemotherapy into vein, 1 hour or less32$34,458$119
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less13$5,322$26
Administration of additional new drug or substance into vein, 1 hour or less14$3,766$59
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle13$2,074$24
Injection of drug or substance under skin or into muscle30$1,639$11
Injection, denosumab, 1 mg28$1None

2019: 14 services

Original Medicare services billed in 2019
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes205$93,865$61
Initial hospital care with moderate level of medical decision making at least 75 minutes240$53,597$166
Administration of chemotherapy into vein, 1 hour or less40$44,466$119
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less26$13,051$27
Administration of additional new drug or substance into vein, 1 hour or less15$5,103$59
Administration of chemotherapy into vein, each additional hour17$2,056$26
Injection of drug or substance under skin or into muscle30$1,955$12
Hospital discharge day management, 30 minutes or less11$750$63
Biopsy of bone marrow11$730$66
Injection, ondansetron hydrochloride, per 1 mg22$24None
Injection, dexamethasone sodium phosphate, 1 mg21$12None
Injection, diphenhydramine hcl, up to 50 mg17$9None
Injection, denosumab, 1 mg23$1None
Injection, nivolumab, 1 mg11$1None

2018: 15 services

Original Medicare services billed in 2018
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes223$120,745$61
Initial hospital care with moderate level of medical decision making at least 75 minutes244$56,252$166
Administration of chemotherapy into vein, 1 hour or less44$46,828$125
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram12$29,223None
Short return visit (20+ min)183$22,365$51
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less36$15,967$28
Administration of additional new drug or substance into vein, 1 hour or less23$6,607$61
Return visit (30+ min)41$6,494$93
Administration of chemotherapy into vein, each additional hour19$3,608$28
Injection of drug or substance under skin or into muscle17$3,258$17
Biopsy of bone marrow17$1,868$110
Hospital discharge day management, 30 minutes or less17$1,506$63
Injection, ondansetron hydrochloride, per 1 mg30$212None
Injection, dexamethasone sodium phosphate, 1 mg27$118None
Injection, diphenhydramine hcl, up to 50 mg22$50None

2017: 21 services

Original Medicare services billed in 2017
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes270$96,249$61
Administration of chemotherapy into vein, 1 hour or less44$74,426$123
Initial hospital care with moderate level of medical decision making at least 75 minutes280$58,465$163
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram15$47,581None
Short return visit (20+ min)238$46,818$58
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less37$23,590$28
Return visit (30+ min)61$12,338$91
Injection of drug or substance under skin or into muscle18$6,046$22
Administration of chemotherapy into vein, each additional hour22$5,999$25
Administration of additional new drug or substance into vein, 1 hour or less17$5,625$59
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour11$5,149$17
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count54$5,089$10
Biopsy of bone marrow21$3,069$139
New patient visit (45+ min)18$2,214$123
New patient visit (30+ min)25$2,087$83
Hospital discharge day management, 30 minutes or less20$2,053$62
Insertion of needle into vein for collection of blood sample60$1,626$3
Injection, ondansetron hydrochloride, per 1 mg33$451None
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service21$239$11
Injection, dexamethasone sodium phosphate, 1 mg27$201None
Injection, diphenhydramine hcl, up to 50 mg20$117None

2016: 23 services

Original Medicare services billed in 2016
Injection, bevacizumab, 10 mg11$255,458None
Administration of chemotherapy into vein, 1 hour or less52$102,097$122
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes266$64,872$61
Initial hospital care with moderate level of medical decision making at least 75 minutes274$60,025$167
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram15$58,250None
Short return visit (20+ min)229$39,994$56
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less48$33,491$27
Return visit (30+ min)53$10,195$89
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count77$9,342$10
Injection, docetaxel, 1 mg11$8,839None
Administration of additional new drug or substance into vein, 1 hour or less18$8,629$56
Administration of chemotherapy into vein, each additional hour30$6,956$25
New patient visit (45+ min)47$6,278$134
Injection of drug or substance under skin or into muscle26$4,684$23
Insertion of needle into vein for collection of blood sample84$2,978$3
Biopsy of bone marrow18$2,579$136
Hospital discharge day management, 30 minutes or less14$1,360$62
New patient visit (30+ min)11$1,028$93
Injection, ondansetron hydrochloride, per 1 mg43$756None
Injection, dexamethasone sodium phosphate, 1 mg32$346None
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service18$206$11
Injection, diphenhydramine hcl, up to 50 mg25$137None
Infusion, normal saline solution, 250 cc13$31None

2015: 24 services

Original Medicare services billed in 2015
Administration of chemotherapy into vein, 1 hour or less48$86,684$121
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram21$76,294None
Initial hospital care with moderate level of medical decision making at least 75 minutes351$71,546$167
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes306$65,957$61
Short return visit (20+ min)207$35,469$58
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less49$30,835$26
Injection, docetaxel, 1 mg15$23,346None
Return visit (30+ min)65$10,421$91
Administration of additional new drug or substance into vein, 1 hour or less20$8,731$56
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count77$8,400$10
Administration of chemotherapy into vein, each additional hour34$6,904$25
Injection of drug or substance under skin or into muscle26$4,529$22
New patient visit (45+ min)30$4,105$137
Insertion of needle into vein for collection of blood sample82$2,652$3
Biopsy of bone marrow17$2,417$142
Hospital discharge day management, 30 minutes or less27$2,412$62
New patient visit (30+ min)15$1,133$76
Infusion into a vein for hydration, 31-60 minutes15$1,082$49
Injection, ondansetron hydrochloride, per 1 mg47$604None
Infusion into a vein for hydration, each additional hour12$461$14
Injection, dexamethasone sodium phosphate, 1 mg41$391None
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service17$183$11
Injection, diphenhydramine hcl, up to 50 mg31$110None
Infusion, normal saline solution, 250 cc39$102None

2014: 23 services

Original Medicare services billed in 2014
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes277$68,819$60
Initial hospital care with moderate level of medical decision making at least 75 minutes298$67,879$167
Administration of chemotherapy into vein, 1 hour or less45$62,365$119
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram17$55,771None
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less51$26,346$26
Short return visit (20+ min)208$21,371$50
Return visit (30+ min)67$9,561$92
Administration of additional new drug or substance into vein, 1 hour or less26$8,675$55
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less16$8,251$60
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count77$7,727$10
Administration of chemotherapy into vein, each additional hour40$7,220$25
New patient visit (45+ min)36$4,617$128
Injection of drug or substance under skin or into muscle21$3,403$22
Hospital discharge day management, 30 minutes or less28$2,810$61
Insertion of needle into vein for collection of blood sample81$2,458$3
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour11$1,762$16
Injection, paclitaxel, 30 mg12$1,523None
New patient visit (30+ min)16$1,407$88
Injection, carboplatin, 50 mg14$1,253None
Injection, ondansetron hydrochloride, per 1 mg42$557None
Injection, dexamethasone sodium phosphate, 1 mg34$295None
Injection, diphenhydramine hcl, up to 50 mg31$139None
Infusion, normal saline solution, 250 cc21$28None

2013: 22 services

Original Medicare services billed in 2013
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes326$79,477$58
Administration of chemotherapy into vein, 1 hour or less39$70,332$129
Initial hospital care with moderate level of medical decision making at least 75 minutes338$68,832$163
Short return visit (20+ min)238$35,101$56
Injection, filgrastim (g-csf), 480 mcg15$33,273None
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less38$24,880$28
Administration of chemotherapy into vein, each additional hour30$12,082$27
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count151$9,436$11
Administration of additional new drug or substance into vein, 1 hour or less16$8,136$64
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less16$7,075$67
Insertion of needle into vein for collection of blood sample152$2,942$3
New patient visit (30+ min)33$2,789$85
Hospital discharge day management, 30 minutes or less29$2,726$59
Biopsy of bone marrow18$2,522$140
Injection of drug or substance under skin or into muscle17$2,230$23
New patient visit (45+ min)17$2,197$129
Return visit (30+ min)20$1,728$82
Injection, ondansetron hydrochloride, per 1 mg34$634None
Injection, dexamethasone sodium phosphate, 1 mg31$223None
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service18$188$10
Injection, diphenhydramine hcl, up to 50 mg19$121None
Infusion, normal saline solution, 250 cc11$13None

Medicaid work

$306,105 in 2024

Medicaid paid $306,105 for 6,456 billed services this clinician did in 2024, up to 149 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Clinic visit/encounter, all-inclusive1,285$261,635
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES1,996$32,447
IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES322$10,763
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug318$554
Return visit (30+ min)1,214$317
Short return visit (20+ min)713$96
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular159$82
1ST HOSP IP/OBS HIGH 7515$80
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)128$74
New patient visit (30+ min)106$57
Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)19$0
Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)100$0
Medicaid work by year
20246,45613149$306,105
20235,80110100$276,548
20227,61217233$421,652
202112,78017287$844,453
202012,00617267$877,618
20198,03016245$619,664
20185,62312259$335,954
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Clinic visit/encounter, all-inclusive1,030$201,991
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES2,241$59,496
IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES275$12,778
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug317$1,394
Return visit (30+ min)826$336
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)109$316
New patient visit (30+ min)80$113
Short return visit (20+ min)614$72
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular254$51
Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes55$0

2022

Largest Medicaid services in 2022
Clinic visit/encounter, all-inclusive1,835$355,660
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES1,933$48,218
IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES204$9,172
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug257$1,571
Return visit (30+ min)1,308$1,211
1ST HOSP IP/OBS HIGH 7513$1,026
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)56$799
COMPREHENSIVE METABOLIC PANEL69$786
CARCINOEMBRYONIC ANTIGEN32$688
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count72$626
Short return visit (20+ min)1,154$570
Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29)38$551

2021

Largest Medicaid services in 2021
Clinic visit/encounter, all-inclusive3,983$766,879
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES1,273$36,617
IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES220$9,777
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug401$5,612
Short return visit (20+ min)3,160$5,283
CARCINOEMBRYONIC ANTIGEN177$3,763
Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29)256$3,488
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)212$3,367
COMPREHENSIVE METABOLIC PANEL263$3,066
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count226$2,064
Return visit (30+ min)957$1,521
Short return visit912$1,332

2020

Largest Medicaid services in 2020
Clinic visit/encounter, all-inclusive4,263$807,930
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES1,276$35,007
IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES175$9,429
Short return visit (20+ min)3,257$7,837
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug237$3,216
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)149$3,003
Return visit (30+ min)676$2,441
Short return visit1,096$2,097
Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29)131$2,065
New patient visit (30+ min)312$1,515
CARCINOEMBRYONIC ANTIGEN54$1,161
COMPREHENSIVE METABOLIC PANEL102$1,085

2019

Largest Medicaid services in 2019
Clinic visit/encounter, all-inclusive2,954$552,937
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES1,121$25,438
IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES218$10,320
Short return visit (20+ min)1,468$6,289
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)342$5,247
Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29)193$4,126
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug460$3,982
Return visit (30+ min)529$3,715
CARCINOEMBRYONIC ANTIGEN91$1,957
COMPREHENSIVE METABOLIC PANEL106$1,258
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count135$1,191
New patient visit (45+ min)119$1,044

2018

Largest Medicaid services in 2018
Clinic visit/encounter, all-inclusive1,448$267,107
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES1,629$27,067
Short return visit (20+ min)706$8,857
IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES264$8,580
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)276$7,051
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug341$5,076
Return visit (30+ min)338$4,815
New patient visit (30+ min)153$4,126
OFF/OP EST MAY X REQ PHY/QHP71$1,170
Injection, ondansetron hydrochloride, per 1 mg207$862
Injection, dexamethasone sodium phosphate, 1 mg164$706
1ST HOSP IP/OBS HIGH 7526$537

Drugs they prescribed that Part D paid

$3,892,633

Pharmacies billed $3,892,633 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 1% of their Part D prescriptions (18 of 1,453) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.

718 generic and 735 brand-name prescriptions · $3,892,633 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Opdivo88$630,988$7,170
Keytruda43$457,744$10,645
Yervoy29$441,664$15,230
Xgeva113$318,179$2,816
Avastin57$243,621$4,274
See all 34 drugs
Every Part D drug this clinician prescribed
Opdivo88$630,988$7,170
Keytruda43$457,744$10,645
Yervoy29$441,664$15,230
Xgeva113$318,179$2,816
Avastin57$243,621$4,274
Enhertu17$171,923$10,113
Tecentriq17$163,643$9,626
Procrit60$162,215$2,704
Polivy14$143,758$10,268
Rituxan23$131,840$5,732
Lupron Depot63$120,122$1,907
Prolia36$55,870$1,552
Fulphila23$45,319$1,970
Fulvestrant26$10,637$409
Xarelto26$10,594$407
Cyclophosphamide28$9,541$341
Pemetrexed Disodium13$4,050$312
Oxaliplatin29$2,827$97
Megestrol Acetate13$1,219$94
Gemcitabine16$1,010$63
Ondansetron82$292$4
Letrozole27$235$9
Constulose11$213$19
Hydrocodone-Acetaminophen12$206$17
Gabapentin22$89$4
Dexamethasone Sodium Phosphate53$81$2
Pantoprazole19$77$4
Diphenhydramine50$75$1
Prednisone32$72$2
Levothyroxine11$69$6
Famotidine15$65$4
Escitalopram15$59$4
Ondansetron15$38$3
Famotidine31$23$1

Year by year

Part D prescribing by year
20241,4531301% (18)51%$3,892,633
20231,5091261% (13)46%$4,708,537
20221,8281651% (15)None$4,991,274
20213,2772055% (160)None$5,806,124
20202,9112023% (84)None$5,786,035
20192,4172015% (129)None$4,894,797
20182,0581795% (100)23%$3,120,567
20171,6151626% (99)20%$1,887,616
20161,8731747% (127)None$1,807,707
20151,36615312% (163)None$1,152,683
20141,8451719% (159)None$1,350,485
20131,8231777% (134)21%$1,021,747

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 42 drugs

Part D drugs prescribed in 2023
Opdivo71$641,573$9,036
Keytruda47$556,595$11,842
Yervoy23$346,304$15,057
Xgeva104$294,059$2,827
Lynparza13$216,193$16,630
Tasigna11$199,932$18,176
Rituxan24$176,319$7,347
Lupron Depot63$129,691$2,059
Avastin28$112,293$4,010
Fulphila21$84,083$4,004
Fulvestrant54$82,372$1,525
Procrit21$71,359$3,398
Prolia31$51,581$1,664
Retacrit20$26,698$1,335
Xarelto52$18,817$362
Cyclophosphamide14$8,212$587
Eliquis12$8,105$675
Oxaliplatin26$6,572$253
Gemcitabine22$2,053$93
Megestrol Acetate11$1,590$145
Letrozole60$1,581$26
Divalproex12$351$29
Famotidine31$256$8
Pantoprazole21$254$12
Ondansetron54$178$3
Carbidopa-Levodopa13$138$11
Alendronate11$134$12
Ibuprofen28$128$5
Dexamethasone Sodium Phosphate50$127$3
Metoclopramide12$122$10
Escitalopram20$113$6
Valproic Acid16$112$7
Levothyroxine12$101$8
Diphenhydramine46$87$2
Atorvastatin17$84$5
Prednisone16$78$5
Bisoprolol16$74$5
Ondansetron16$71$4
Albuterol Sulfate18$61$3
Ipratropium17$54$3
Furosemide11$41$4
Famotidine26$36$1

2022: 48 drugs

Part D drugs prescribed in 2022
Opdivo88$708,301$8,049
Yervoy29$472,603$16,297
Afinitor25$413,502$16,540
Xgeva125$335,543$2,684
Ibrance21$329,567$15,694
Verzenio19$241,552$12,713
Venclexta13$120,773$9,290
Avastin25$112,780$4,511
Lupron Depot60$106,404$1,773
Fulphila29$105,974$3,654
Fulvestrant67$98,342$1,468
Herceptin17$70,564$4,151
Decitabine22$63,275$2,876
Procrit17$61,413$3,613
Prolia21$29,463$1,403
Trelstar28$26,882$960
Retacrit15$21,444$1,430
Eliquis25$17,656$706
Xarelto34$12,508$368
Docetaxel14$8,445$603
Exemestane13$3,340$257
Oxaliplatin27$2,836$105
Letrozole105$2,664$25
Carboplatin26$1,562$60
Loperamide17$1,512$89
Paclitaxel14$1,346$96
Fluorouracil15$1,188$79
Gemcitabine12$744$62
Duloxetine18$702$39
Hydrocodone-Acetaminophen11$447$41
Metoclopramide16$402$25
Levothyroxine20$353$18
Ibuprofen40$297$7
Ondansetron74$294$4
Gabapentin12$266$22
Dexamethasone Sodium Phosphate23$255$11
Ondansetron19$235$12
Carbidopa-Levodopa17$193$11
Anastrozole15$183$12
Dexamethasone Sodium Phosphate56$178$3
Pantoprazole17$149$9
Diphenhydramine46$147$3
Atorvastatin18$139$8
Benztropine Mesylate11$114$10
Famotidine14$114$8
Alendronate15$94$6
Sertraline15$91$6
Famotidine23$47$2

2021: 78 drugs

Part D drugs prescribed in 2021
Opdivo62$697,631$11,252
Ibrance42$604,401$14,391
Avastin93$582,964$6,268
Afinitor27$444,386$16,459
Verzenio25$355,501$14,220
Xgeva137$338,752$2,473
Tukysa14$285,040$20,360
Tasigna13$224,100$17,238
Rituxan16$135,208$8,450
Lupron Depot70$127,339$1,819
Fulvestrant73$107,895$1,478
Herceptin25$103,841$4,154
Neulasta11$74,410$6,765
Decitabine16$42,288$2,643
Prolia24$31,920$1,330
Eliquis44$31,818$723
Trelstar31$26,696$861
Retacrit27$25,554$946
Doxorubicin Hcl Liposome14$22,371$1,598
Xarelto30$16,703$557
Oxycontin17$14,325$843
Anagrelide38$12,384$326
Docetaxel16$5,619$351
Megestrol Acetate78$4,839$62
Oxaliplatin49$4,588$94
Symbicort11$4,366$397
Hydrocodone-Acetaminophen103$3,787$37
Letrozole214$3,507$16
Ondansetron70$2,833$40
Leucovorin13$2,603$200
Fluorouracil36$2,159$60
Loperamide27$2,053$76
Lidocaine11$1,881$171
Irinotecan18$1,577$88
Bicalutamide47$1,569$33
Gemcitabine18$1,536$85
Cyclobenzaprine19$1,300$68
Exemestane11$1,129$103
Diclofenac32$988$31
Carboplatin23$929$40
Gabapentin53$868$16
Rosuvastatin19$797$42
Hydroxyurea14$796$57
Ventolin Hfa13$765$59
Baclofen25$738$30
Omeprazole63$691$11
Duloxetine30$606$20
Levothyroxine37$481$13
Anastrozole22$404$18
Dexamethasone15$395$26
Ondansetron102$385$4
Prednisone60$368$6
Oxybutynin Chloride17$334$20
Pantoprazole36$323$9
Zolpidem46$280$6
Dexamethasone Sodium Phosphate100$254$3
Atorvastatin33$242$7
Tamsulosin13$218$17
Potassium Chloride21$216$10
Losartan15$216$14
Alendronate40$213$5
Alprazolam11$207$19
Hydrocortisone27$199$7
Metoclopramide21$192$9
Losartan-Hydrochlorothiazide12$191$16
Amlodipine Besylate31$181$6
Sertraline37$154$4
Ibuprofen14$142$10
Diphenhydramine47$123$3
Carbidopa-Levodopa11$120$11
Benazepril19$115$6
Famotidine19$112$6
Azithromycin13$92$7
Hydrochlorothiazide11$76$7
Metoprolol14$69$5
Triamcinolone Acetonide12$63$5
Tramadol11$59$5
Glipizide12$24$2

2020: 64 drugs

Part D drugs prescribed in 2020
Ibrance52$685,590$13,184
Avastin60$476,001$7,933
Opdivo65$445,838$6,859
Yervoy25$390,116$15,605
Xgeva156$340,226$2,181
Xtandi20$245,335$12,267
Lynparza16$237,823$14,864
Enhertu29$228,549$7,881
Afinitor14$207,707$14,836
Rituxan19$153,141$8,060
Zytiga14$142,175$10,155
Keytruda14$135,870$9,705
Tecentriq11$118,785$10,799
Lupron Depot55$106,110$1,929
Fulvestrant70$102,548$1,465
Jakafi12$87,860$7,322
Azacitidine21$76,939$3,664
Empliciti13$69,445$5,342
Aranesp27$51,179$1,896
Anagrelide37$28,180$762
Prolia22$26,339$1,197
Eliquis40$26,172$654
Xarelto47$22,766$484
Toremifene Citrate12$13,470$1,123
Cyclophosphamide22$9,079$413
Symbicort15$8,654$577
Megestrol Acetate78$4,524$58
Letrozole225$2,559$11
Lidocaine12$2,291$191
Ondansetron62$1,993$32
Hydrocodone-Acetaminophen57$1,321$23
Baclofen20$1,036$52
Diclofenac27$987$37
Dexamethasone24$888$37
Bicalutamide41$818$20
Loperamide17$719$42
Hydroxyurea15$713$48
Duloxetine33$703$21
Cyclobenzaprine15$673$45
Albuterol Sulfate Hfa16$544$34
Gabapentin55$478$9
Potassium Chloride23$449$20
Omeprazole70$432$6
Ondansetron62$424$7
Ibuprofen42$406$10
Levothyroxine26$373$14
Atorvastatin46$360$8
Prednisone69$322$5
Dexamethasone Sodium Phosphate63$260$4
Pantoprazole41$243$6
Zolpidem39$200$5
Diphenhydramine54$183$3
Anastrozole23$180$8
Alendronate47$174$4
Carbidopa-Levodopa13$141$11
Hydrocortisone35$139$4
Sertraline37$134$4
Tamsulosin16$111$7
Triamcinolone Acetonide14$85$6
Famotidine18$68$4
Allopurinol11$57$5
Amlodipine Besylate15$56$4
Tramadol12$39$3
Benazepril12$38$3

2019: 58 drugs

Part D drugs prescribed in 2019
Afinitor49$759,268$15,495
Ibrance39$472,634$12,119
Opdivo37$418,797$11,319
Tecentriq42$361,102$8,598
Revlimid15$304,858$20,324
Avastin43$260,923$6,068
Xgeva74$171,962$2,324
Rituxan12$128,489$10,707
Keytruda14$106,094$7,578
Velcade13$84,028$6,464
Faslodex33$66,013$2,000
Lupron Depot21$50,505$2,405
Azacitidine12$35,758$2,980
Zarxio11$29,430$2,675
Xarelto45$23,345$519
Prolia18$19,843$1,102
Anagrelide43$16,686$388
Eliquis39$16,382$420
Oxycontin12$13,066$1,089
Cyclophosphamide13$10,424$802
Exemestane34$7,636$225
Megestrol Acetate69$4,516$65
Dexilant12$4,010$334
Letrozole196$2,835$14
Docetaxel15$2,179$145
Gemcitabine12$2,075$173
Hydrocodone-Acetaminophen72$1,578$22
Carboplatin12$870$72
Hydroxyurea24$790$33
Gabapentin57$708$12
Doxorubicin12$585$49
Duloxetine27$547$20
Ondansetron80$546$7
Ondansetron55$481$9
Levothyroxine31$445$14
Dexamethasone18$411$23
Bicalutamide16$367$23
Tamoxifen Citrate11$346$31
Anastrozole29$343$12
Atorvastatin34$320$9
Ranitidine15$307$20
Omeprazole23$285$12
Dexamethasone Sodium Phosphate64$242$4
Pantoprazole33$230$7
Ibuprofen25$204$8
Hydromorphone19$204$11
Diphenhydramine55$196$4
Prednisone30$181$6
Alendronate42$180$4
Metoprolol11$171$16
Zolpidem23$160$7
Carbidopa-Levodopa12$127$11
Metoclopramide12$102$9
Hydrocortisone16$79$5
Levofloxacin11$76$7
Tramadol20$75$4
Montelukast11$69$6
Dexamethasone Sodium Phosphate12$64$5

2018: 53 drugs

Part D drugs prescribed in 2018
Afinitor30$445,352$14,845
Ibrance26$301,251$11,587
Stivarga18$292,679$16,260
Jakafi16$206,465$12,904
Pomalyst11$193,666$17,606
Tasigna14$182,036$13,003
Sutent15$180,700$12,047
Opdivo12$147,718$12,310
Rituxan13$145,363$11,182
Neupogen15$49,891$3,326
Procrit12$45,088$3,757
Xgeva19$43,509$2,290
Azacitidine12$32,585$2,715
Anagrelide46$20,851$453
Aranesp12$17,409$1,451
Oxycontin11$11,754$1,069
Xarelto25$10,336$413
Eliquis23$9,122$397
Megestrol Acetate54$3,224$60
Leucovorin13$2,048$158
Letrozole197$1,968$10
Hydroxyurea25$1,331$53
Hydrocodone-Acetaminophen57$1,176$21
Anastrozole135$1,111$8
Duloxetine41$1,019$25
Tamoxifen Citrate33$989$30
Ondansetron54$702$13
Gabapentin69$602$9
Levothyroxine32$516$16
Carboplatin12$484$40
Fluorouracil12$480$40
Dexamethasone16$377$24
Tamsulosin20$280$14
Prednisone45$262$6
Alendronate63$245$4
Ondansetron40$239$6
Metoclopramide31$236$8
Metoprolol12$228$19
Ibuprofen24$168$7
Hydromorphone17$164$10
Atorvastatin15$161$11
Prochlorperazine Maleate14$155$11
Dexamethasone Sodium Phosphate38$143$4
Warfarin15$131$9
Diphenhydramine27$122$5
Zolpidem18$112$6
Omeprazole14$112$8
Dexamethasone Sodium Phosphate12$98$8
Allopurinol11$90$8
Pantoprazole18$83$5
Benazepril12$69$6
Furosemide15$32$2
Potassium Chloride11$27$2

2017: 38 drugs

Part D drugs prescribed in 2017
Jakafi18$216,798$12,044
Stivarga12$180,684$15,057
Tasigna15$173,886$11,592
Vectibix13$172,778$13,291
Afinitor12$157,684$13,140
Procrit31$117,653$3,795
Anagrelide34$11,260$331
Exemestane20$7,581$379
Megestrol Acetate49$3,173$65
Esomeprazole Magnesium17$2,331$137
Letrozole163$1,704$10
Duloxetine62$1,562$25
Hydrocodone-Acetaminophen70$1,107$16
Anastrozole117$1,091$9
Tamoxifen Citrate29$895$31
Gabapentin66$503$8
Tamsulosin22$434$20
Metoprolol14$391$28
Hydroxyurea14$390$28
Alendronate59$356$6
Warfarin44$342$8
Doxepin11$319$29
Ondansetron27$252$9
Prednisone42$244$6
Diphenoxylate-Atropine11$191$17
Spironolactone11$147$13
Zolpidem20$128$6
Pantoprazole21$125$6
Hydromorphone11$124$11
Quetiapine11$117$11
Sertraline23$105$5
Prochlorperazine Maleate14$77$6
Ibuprofen18$65$4
Donepezil11$62$6
Benazepril11$61$6
Famotidine11$56$5
Amlodipine Besylate15$45$3
Furosemide21$44$2

2016: 52 drugs

Part D drugs prescribed in 2016
Revlimid37$506,640$13,693
Afinitor19$235,602$12,400
Tasigna18$190,707$10,595
Jakafi17$179,778$10,575
Stivarga12$165,528$13,794
Promacta11$96,926$8,811
Procrit20$71,855$3,593
Anagrelide32$10,990$343
Xarelto19$8,177$430
Eliquis12$3,914$326
Crestor12$3,479$290
Exemestane27$3,362$125
Lyrica16$2,738$171
Letrozole168$2,580$15
Megestrol Acetate36$2,252$63
Hydrocodone-Acetaminophen76$2,060$27
Temazepam15$1,875$125
Tolterodine11$1,626$148
Tamoxifen Citrate43$795$18
Ibandronate17$715$42
Gabapentin100$675$7
Anastrozole91$654$7
Duloxetine19$528$28
Warfarin73$434$6
Tamsulosin29$381$13
Ondansetron37$334$9
Fenofibrate11$320$29
Prednisone39$312$8
Bicalutamide17$307$18
Metoprolol12$276$23
Metoclopramide40$270$7
Diphenoxylate-Atropine18$240$13
Hydromorphone18$240$13
Alendronate43$238$6
Quetiapine16$233$15
Glyburide11$202$18
Pantoprazole32$200$6
Zolpidem40$191$5
Doxepin11$186$17
Spironolactone14$164$12
Ibuprofen28$149$5
Sertraline40$142$4
Clopidogrel15$88$6
Prochlorperazine Maleate14$76$5
Sulfamethoxazole-Trimethoprim19$67$4
Glipizide16$65$4
Amiodarone11$64$6
Famotidine17$61$4
Furosemide17$61$4
Donepezil12$56$5
Alprazolam22$55$2
Amlodipine Besylate15$47$3

2015: 37 drugs

Part D drugs prescribed in 2015
Revlimid32$377,039$11,782
Erbitux20$156,005$7,800
Thalomid11$94,758$8,614
Exemestane20$5,234$262
Lyrica27$4,423$164
Hydrocodone-Acetaminophen91$2,985$33
Temazepam17$2,738$161
Megestrol Acetate29$2,621$90
Morphine Sulfate Er18$730$41
Letrozole79$686$9
Anastrozole82$646$8
Gabapentin72$544$8
Tamoxifen Citrate17$439$26
Metoprolol13$436$34
Diphenoxylate-Atropine25$375$15
Tamsulosin15$366$24
Hydromorphone22$365$17
Fenofibrate12$348$29
Zolpidem21$343$16
Nystatin13$330$25
Bicalutamide19$285$15
Warfarin33$252$8
Metoclopramide45$248$6
Levothyroxine17$245$14
Ondansetron17$237$14
Alendronate24$166$7
Sertraline34$165$5
Amlodipine Besylate19$132$7
Enalapril Maleate12$130$11
Pantoprazole11$124$11
Glipizide25$117$5
Famotidine15$96$6
Ibuprofen12$92$8
Sulfamethoxazole-Trimethoprim19$68$4
Prednisone13$63$5
Clopidogrel11$52$5
Alprazolam11$47$4

2014: 49 drugs

Part D drugs prescribed in 2014
Revlimid26$291,595$11,215
Tasigna22$194,485$8,840
Erbitux18$147,853$8,214
Sutent12$85,621$7,135
Anagrelide30$22,491$750
Nexium26$6,267$241
Exemestane16$4,376$273
Letrozole131$4,039$31
Prochlorperazine Maleate16$2,421$151
Tolterodine Tartrate Er12$2,167$181
Hydrocodone-Acetaminophen65$2,141$33
Anastrozole67$1,792$27
Compro12$1,679$140
Ibandronate15$1,584$106
Megestrol Acetate41$1,504$37
Gabapentin104$1,343$13
Fluconazole24$995$41
Oxycodone12$993$83
Morphine Sulfate Er16$726$45
Tamoxifen Citrate34$655$19
Tamsulosin18$536$30
Alendronate63$532$8
Metoprolol17$523$31
Hydromorphone30$498$17
Levothyroxine34$417$12
Warfarin52$409$8
Dexamethasone16$393$25
Amlodipine Besylate52$376$7
Synthroid11$314$29
Levofloxacin16$305$19
Diphenoxylate-Atropine19$302$16
Metoclopramide49$281$6
Quetiapine15$259$17
Famotidine27$225$8
Zolpidem35$222$6
Ondansetron23$220$10
Lactulose13$219$17
Omeprazole13$218$17
Montelukast11$195$18
Prednisone20$182$9
Sertraline34$168$5
Ibuprofen18$165$9
Pantoprazole19$129$7
Atorvastatin13$127$10
Allopurinol11$79$7
Alprazolam14$72$5
Donepezil11$66$6
Metformin12$60$5
Benazepril11$43$4

2013: 45 drugs

Part D drugs prescribed in 2013
Revlimid22$255,732$11,624
Tasigna29$231,804$7,993
Sutent11$62,483$5,680
Thalomid11$46,850$4,259
Docetaxel14$37,728$2,695
Anagrelide48$16,723$348
Nexium43$9,289$216
Letrozole199$5,409$27
Xarelto12$3,463$289
Lyrica16$2,975$186
Megestrol Acetate34$2,410$71
Carboplatin13$1,914$147
Ibandronate17$1,801$106
Prochlorperazine Maleate14$1,318$94
Anastrozole35$908$26
Alendronate86$796$9
Fluconazole27$761$28
Hydrocodone-Acetaminophen57$660$12
Gabapentin75$600$8
Hydroxyurea27$595$22
Ondansetron28$554$20
Omeprazole30$475$16
Hydromorphone24$462$19
Dexamethasone19$443$23
Diclofenac18$439$24
Tamoxifen Citrate24$377$16
Warfarin54$366$7
Metoclopramide53$355$7
Amlodipine Besylate56$353$6
Montelukast13$300$23
Famotidine33$293$9
Glyburide12$209$17
Levothyroxine21$205$10
Tamsulosin12$185$15
Ibuprofen32$182$6
Naproxen20$150$8
Levofloxacin16$150$9
Zolpidem19$147$8
Tramadol16$143$9
Prednisone26$127$5
Atenolol20$86$4
Simvastatin12$74$6
Sertraline11$62$6
Alprazolam15$61$4
Benazepril11$54$5

Money from drug and device companies

$117 in 2025

Industry payments by year
202545None$117
202422None$57
202333None$161
202211None$20
202111None$65
20201222None$412
20191876None$1,253

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
E.R. Squibb & Sons L.L.C.Opdualag$48
2 payments
  • Meals for Opdualag · 2025-08-20 · $21
  • Meals for Opdualag · 2025-05-14 · $26
IncyteJakafi$26
1 payment
  • Meals for Jakafi · 2025-01-14 · $26
EisaiLenvima$23
1 payment
  • Meals for Lenvima · 2025-08-27 · $23
Gilead SciencesTrodelvy$20
1 payment
  • Meals for Trodelvy · 2025-09-17 · $20
See all 5 published payments
Every published payment
Gilead SciencesMeals · 2025-09-17Trodelvy$20
EisaiMeals · 2025-08-27Lenvima$23
E.R. Squibb & Sons L.L.C.Meals · 2025-08-20Opdualag$21
E.R. Squibb & Sons L.L.C.Meals · 2025-05-14Opdualag$26
IncyteMeals · 2025-01-14Jakafi$26
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $57

Payments by company in 2024
Adaptive BiotechnologiesClonoseq$35
1 payment
  • Meals for Clonoseq · 2024-05-29 · $35
AbbvieElahere$21
1 payment
  • Meals for Elahere · 2024-05-21 · $21

2023: $161

Payments by company in 2023
IncyteMonjuvi$125
1 payment
  • Meals for Monjuvi · 2023-03-03 · $125
NovocureOptune$21
1 payment
  • Meals for Optune · 2023-05-26 · $21
Takeda Pharmaceuticals U.S.A.None$16
1 payment
  • Meals · 2023-09-29 · $16

2022: $20

Payments by company in 2022
PfizerIbrance$20
1 payment
  • Meals for Ibrance · 2022-08-03 · $20

2021: $65

Payments by company in 2021
Lilly USAVerzenio$65
1 payment
  • Education for Verzenio · 2021-06-21 · $65

2020: $412

Payments by company in 2020
E.R. Squibb & Sons L.L.C.Opdivo$92
5 payments
  • Meals for Opdivo · 2020-03-13 · $19
  • Meals for Opdivo · 2020-03-06 · $16
  • Meals for Opdivo · 2020-02-21 · $24
  • Meals for Opdivo · 2020-02-05 · $19
  • Meals for Eliquis · 2020-01-08 · $13
Merck Sharp & DohmeKeytruda$63
4 payments
  • Meals · 2020-02-28 · $16
  • Meals for Keytruda · 2020-02-11 · $17
  • Meals for Keytruda · 2020-01-29 · $14
  • Meals for Keytruda · 2020-01-28 · $15
Novartis PharmaceuticalsKisqali$49
2 payments
  • Meals for Piqray · 2020-02-25 · $23
  • Meals for Kisqali · 2020-01-09 · $26
PfizerIbrance$46
3 payments
  • Meals for Ibrance · 2020-03-02 · $14
  • Meals for Inlyta · 2020-02-06 · $19
  • Meals for Ibrance · 2020-01-21 · $14
Puma BiotechnologyNerlynx$25
1 payment
  • Meals for Nerlynx · 2020-02-18 · $25
Daiichi SankyoEnhertu$25
1 payment
  • Meals for Enhertu · 2020-02-13 · $25
Bayer HealthCare PharmaceuticalsStivarga$22
1 payment
  • Meals for Stivarga · 2020-01-13 · $22
AstraZeneca Pharmaceuticals LPLynparza$21
1 payment
  • Meals for Lynparza · 2020-01-22 · $21
Genentech USATecentriq$20
1 payment
  • Meals for Tecentriq · 2020-01-17 · $20
GlaxoSmithKlineZejula$18
1 payment
  • Meals for Zejula · 2020-02-26 · $18
Mylan InstitutionalOgivri$17
1 payment
  • Meals for Ogivri · 2020-02-19 · $17
Advanced Accelerator ApplicationsLutathera$15
1 payment
  • Meals for Lutathera · 2020-02-27 · $15

2019: $1,253

Payments by company in 2019
E.R. Squibb & Sons L.L.C.Opdivo$295
23 payments
  • Meals · 2019-12-05 · $21
  • Meals · 2019-12-05 · $1
  • Meals for Opdivo · 2019-10-24 · $18
  • Meals for Opdivo · 2019-09-17 · $14
  • Meals for Empliciti · 2019-08-26 · $21
  • Meals for Empliciti · 2019-08-26 · $2
  • Meals for Opdivo · 2019-08-13 · $15
  • Meals for Opdivo · 2019-07-22 · $17
  • Meals for Opdivo · 2019-06-25 · $19
  • Meals for Opdivo · 2019-06-18 · $19
  • Meals for Opdivo · 2019-05-31 · $15
  • Meals · 2019-04-30 · $11
  • Meals for Empliciti · 2019-04-23 · $21
  • Meals for Empliciti · 2019-04-23 · $1
  • Meals for Eliquis · 2019-04-15 · $14
  • Meals for Opdivo · 2019-03-28 · $16
  • Meals for Opdivo · 2019-03-27 · $16
  • Meals for Empliciti · 2019-02-20 · $1
  • Meals for Empliciti · 2019-02-20 · $17
  • Meals for Empliciti · 2019-01-29 · $1
  • Meals for Empliciti · 2019-01-29 · $2
  • Meals for Empliciti · 2019-01-29 · $19
  • Meals for Opdivo · 2019-01-15 · $16
Genentech USATecentriq$178
7 payments
  • Meals for Alecensa · 2019-12-06 · $22
  • Meals for Tecentriq · 2019-11-04 · $16
  • Education for Tecentriq · 2019-10-18 · $75
  • Meals for Tecentriq · 2019-09-25 · $3
  • Meals for Tecentriq · 2019-08-21 · $18
  • Meals for Tecentriq · 2019-07-09 · $24
  • Meals for Tecentriq · 2019-05-23 · $21
PfizerIbrance$147
16 payments
  • Meals for Ibrance · 2019-11-22 · $12
  • Meals for Bosulif · 2019-10-22 · $9
  • Meals for Ibrance · 2019-10-16 · $14
  • Meals for Ibrance · 2019-10-15 · $1
  • Meals for Ibrance · 2019-08-20 · $1
  • Meals for Ibrance · 2019-08-20 · $14
  • Meals for Eliquis · 2019-08-09 · $14
  • Meals for Eliquis · 2019-08-09 · $1
  • Meals for Ibrance · 2019-05-06 · $7
  • Meals for Ibrance · 2019-04-10 · $11
  • Meals for Ibrance · 2019-04-10 · $1
  • Meals for Sutent · 2019-03-04 · $17
  • Meals for Eliquis · 2019-03-01 · $20
  • Meals for Ibrance · 2019-02-01 · $8
  • Meals for Ibrance · 2019-02-01 · $2
  • Education for Ibrance · 2019-01-23 · $15
Merck Sharp & DohmeKeytruda$108
6 payments
  • Meals for Keytruda · 2019-12-17 · $16
  • Meals · 2019-10-23 · $18
  • Meals · 2019-05-21 · $19
  • Meals for Keytruda · 2019-05-10 · $18
  • Meals for Keytruda · 2019-02-19 · $19
  • Meals for Keytruda · 2019-01-16 · $19
AmgenNplate$92
4 payments
  • Meals for Kanjinti · 2019-09-26 · $19
  • Meals for Nplate · 2019-05-02 · $26
  • Meals for Nplate · 2019-03-05 · $25
  • Meals for Nplate · 2019-02-05 · $23
Bayer HealthCare PharmaceuticalsStivarga$74
4 payments
  • Meals for Vitrakvi · 2019-11-05 · $16
  • Meals for Stivarga · 2019-10-03 · $18
  • Meals for Stivarga · 2019-08-22 · $17
  • Meals for Nexavar · 2019-03-21 · $24
Gilead SciencesNone$63
3 payments
  • Meals · 2019-12-17 · $21
  • Meals · 2019-08-27 · $25
  • Meals · 2019-05-06 · $17
AstraZeneca Pharmaceuticals LPLynparza$60
3 payments
  • Meals for Lynparza · 2019-11-07 · $19
  • Meals for Lynparza · 2019-08-14 · $23
  • Meals for Lynparza · 2019-03-07 · $18
Takeda Pharmaceuticals U.S.A.Ninlaro$33
1 payment
  • Meals for Ninlaro · 2019-02-15 · $33
ExelixisCabometyx$30
1 payment
  • Meals for Cabometyx · 2019-09-09 · $30
TesaroZejula$29
1 payment
  • Meals for Zejula · 2019-04-19 · $29
Janssen BiotechDarzalex$24
1 payment
  • Meals for Darzalex · 2019-05-24 · $24
Novartis PharmaceuticalsMekinist$24
1 payment
  • Meals for Mekinist · 2019-12-19 · $24
Lilly USAAlimta$23
1 payment
  • Meals for Alimta · 2019-11-18 · $23
EisaiLenvima$22
1 payment
  • Meals for Lenvima · 2019-11-05 · $22
Advanced Accelerator ApplicationsLutathera$18
1 payment
  • Meals for Lutathera · 2019-12-11 · $18
Janssen PharmaceuticalsXarelto$18
1 payment
  • Meals for Xarelto · 2019-04-22 · $18
GenzymeCablivi$14
1 payment
  • Meals for Cablivi · 2019-05-03 · $14

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Seagen Inc. · A Phase 1 Study of Sgn-Tgt in Subjects With Advanced Malignancies · 2023Their institution$82,166
Merck Sharp & Dohme LLC · An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of Inbrx 106 and Inbrx-106 in Combination With Pembrolizumab in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2025Their institution$53,820
PFIZER INC. · A Phase 3 Randomized Openlabel Multicenter Trial of Arv471 Pf07850327 Vs Fulvestrant in Participants With Estrogen Receptorpositive Her2negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease Veritac2 · 2024Their institution$30,617
Amgen Inc. · A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Amg 193 Alone and in Combination With Docetaxel in Subjects With Advanced Mtap-Null Solid Tumors · 2025Their institution$29,000
PFIZER INC. · A Phase 1 Study of Sgntgt in Subjects With Advanced Malignancies · 2024Their institution$24,128
Incyte Corporation · A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response To Ruxolitinib · 2023Their institution$20,000
Incyte Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Pi3kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis · 2022Their institution$20,000
Eli Lilly and Company · Study of Loxo-305 Versus Investigator'S Choice (Idelar Or Br) in Patients With Previously Treated Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (Sll) (Bruin Cll-321) · 2021Their institution$15,817
Merck Sharp & Dohme LLC · An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of Inbrx 106 and Inbrx-106 in Combination With Pembrolizumab in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2024Their institution$15,760
Veru Inc. · Veru V3002401 4063 01 · 2023Their institution$15,695
Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2022Their institution$13,715
BioNTech SE · 2022Their institution$13,500
AstraZeneca UK Limited · An Observational,Prospective,Multicenter Study of Non Small Cell Lung Cancer Patients in the US Receiving Standard of Care and Initiating An Approved Therapy With Risk of Pneumonitis Ild · 2025Their institution$12,755
Daiichi Sankyo Inc. · Enhertu · 2025Their institution$12,302
Exeltis, USA Inc. · Slynd · 2024Their institution$11,800
AstraZeneca UK Limited · An Observational,Prospective,Multicenter Study of Non Small Cell Lung Cancer Patients in the US Receiving Standard of Care and Initiating An Approved Therapy With Risk of Pneumonitis Ild · 2024Their institution$10,100
Eli Lilly and Company · A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 2022Their institution$9,714
Eli Lilly and Company · Study of Loxo-305 Versus Investigator'S Choice (Idelar Or Br) in Patients With Previously Treated Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (Sll) (Bruin Cll-321) · 2022Their institution$8,269
Eli Lilly and Company · Study of Loxo-305 Versus Investigator'S Choice (Idelar Or Br) in Patients With Previously Treated Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (Sll) (Bruin Cll-321) · 2024Their institution$7,850
Eli Lilly and Company · A Phase 3 Open-Label Randomized Study of Pirtobrutinib (Loxo-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 2023Their institution$6,274
Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2023Their institution$5,150
Becton, Dickinson and Company · 2021Their institution$5,000
PFIZER INC. · A Phase 3 Randomized Openlabel Multicenter Trial of Arv471 Pf07850327 Vs Fulvestrant in Participants With Estrogen Receptorpositive Her2negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease Veritac2 · 2025Their institution$4,495
Incyte Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Pi3kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis · 2025Their institution$4,000
Incyte Corporation · A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response To Ruxolitinib · 2025Their institution$4,000
Amgen Inc. · A Phase 1 Fih Prmt5i Therapy for Treatment of Mtap Null Nscls · 2024Their institution$2,680
Amgen Inc. · P3 1l Crc Triplet Cb 301 · 2024Their institution$1,504
BioNTech SE · 2024Their institution$1,414
Daiichi Sankyo Inc. · 2025Their institution$1,401
Eli Lilly and Company · Study of Loxo-305 Versus Investigator'S Choice (Idelar Or Br) in Patients With Previously Treated Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (Sll) (Bruin Cll-321) · 2023Their institution$1,261
Eli Lilly and Company · A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 2024Their institution$9

Professional record

NPI
1679590566
Licence
CA A52470California A52470: Current · expires 2027-04-30
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
CA 00A524700
Taxonomy
Federal specialty code 207RH0003X (207RH0003X)
Mailing address
Po Box 6, La Canada, CA, 91012
NPI first listed
2006-07-16
NPI last updated
2007-07-09

This is when the NPI record was last certified, not a medical board exam.